News

Dr. Suzette Delaloge Receives the Grand Prix de la Recherche Ruban Rose

A medical oncologist at Gustave Roussy and director of the personalised prevention program Interception, Dr. Suzette Delaloge has been honoured by the Ruban Rose Association for her research aimed at developing a saliva test capable of detecting early signs of breast cancer.

Published on

Remise du prix

Dr. Suzette Delaloge, an international expert in breast cancer and personalised prevention, received the Grand Prix de la Recherche Ruban Rose on Thursday, January 16, at the French National Assembly.

This prestigious award, endowed with €350,000, supports an innovative research project she is leading. It aims to identify early warning signals, detectable at least three years before the onset of the disease, which could predict the occurrence of breast cancer.

"We will analyse the saliva of 200 women who have developed breast cancer as part of our large international study, MyPeBS, and compare it to the saliva of 200 women with the same initial characteristics but who did not develop the disease," explains Dr. Delaloge. "The goal is to identify a profile of genetic modifications in salivary DNA (including methylation) associated with the development of breast cancer in the following years," she adds.

Saliva tests have the advantage of being non-invasive and cost-effective. Ultimately, this research program aims to develop a saliva-based prevention test focused on breast cancer, which could be implemented across France.

"Like many oncologists, my motivation is intrinsic," says Dr. Delaloge. "What drives us, what fuels these programs, what continuously pushes us to go further is the desire to prevent cancer from occurring, to ensure it is diagnosed earlier, and if cancer does develop, to improve treatments and increase the chances of recovery," she continues.

This project is part of the Interception program, conceived by Dr. Delaloge and launched in 2021. Interception is based on a comprehensive approach to personalised prevention. It has already been applied to several pathways tailored to specific cancer types or risk factors. In 2024, the first Interception pathways were introduced in several partner centres across France, with more set to open in mainland France and overseas territories in 2025.

Last news

  • Two photon-counting CT scanners now equip Gustave Roussy's imaging department

    Since September 2026, Gustave Roussy's Department of Medical Imaging has been equipped with a second photon-counting CT scanner, delivering higher image resolution while reducing the doses of X-rays and contrast agent administered to patients. This technology recently enabled the Institute to perform an iodine-free pulmonary CT angiogram, a world first.

    Photographie du scanner à comptage photonique
  • Prevention and screening: getting ahead of lung cancer

    To mark Thoracic Cancer Awareness Month and Tobacco-Free Month, two campaigns focusing on lung cancer, Gustave Roussy highlights its initiatives to advance prevention and screening among people at increased risk. Since its creation in 2021, the Institute’s Interception Lung programme has welcomed more than 900 participants, supporting them to stop smoking and offering personalised screening for the disease.

    Photographie : patient effectuant un scanner thoracique et équipes soignantes
  • Gustave Roussy Meets His Audience

    As part of its awareness-raising and fundraising efforts, Gustave Roussy is currently conducting a door-to-door outreach campaign in several towns in Val-de-Marne (Fresnes, Vitry-sur-Seine, Nogent-sur-Marne, Bry-sur-Marne, Le Kremlin-Bicêtre) from Monday through Saturday, 1:30 p.m. to 8:00 p.m.

    Deux personnes en charge de la collecte porte-à-porte
  • Mens November: Take care of your jewelry its precious!

    November is the month dedicated to raising awareness and promoting prevention of male cancers, which include prostate, testicular, and penile cancers. The goal is to raise public awareness of these diseases—which account for approximately 63,000 new cases in France each year—and to encourage men to perform testicular self-exams, a simple step that can help detect a lump, the nature of which must then be determined through further medical examinations. Gustave Roussy has extensive expertise in the treatment of male cancers, particularly through its Genitourinary Oncology Committee, which is deeply involved in research on these diseases. 

    Visuel fixe campagne novembre masculin